# Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes

> **NCT00624364** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 140 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT00624364
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624364, "Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00624364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*